Safety, tolerability, and initial efficacy of AZD6140, the first reversivle oral adenosine diphosphate receptor antagonist, compared with clopidigrel, in patients with non-ST-segment elevation acute coronary syndrome - Primary results of the DISPERSE-2 trial JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY Cannon, C. P., Husted, S., Harrington, R. A., Scirica, B. M., Emanuelsson, H., Storey, R. F. 2007; 50 (19): 1844-1851

View details for DOI 10.1016/j.jacc.2007.07.053

View details for Web of Science ID 000250788300005